Tat exon 1 exhibits functional diversity during HIV-1 subtype C primary infection

Journal of Virology

Volumn 87, Issue 10, 2013, Pages 5732-5745

  Rossenkhan, Raabya ^a,b,c   MacLeod, Iain J ^b,c   Sebunya, Theresa K ^a   Castro Nallar, Eduardo ^d,e   McLane, Mary Fran ^b   Musonda, Rosemary ^b,c   Gashe, Berhanu A ^a   Novitsky, Vlad ^b,c   Essex, M ^b,c  

^a UNIVERSITY OF BOTSWANA   (Botswana)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^d BRIGHAM YOUNG UNIVERSITY   (United States)

^e GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; HLA B ANTIGEN; TRANSACTIVATOR PROTEIN; VIRUS RNA;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DNA POLYMORPHISM; EXON; FEMALE; GENE AMPLIFICATION; GENE INTERACTION; GENE MUTATION; GENE SEQUENCE; GENETIC SELECTION; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LONG TERMINAL REPEAT; MALE; MOLECULAR DYNAMICS; MOLECULAR EVOLUTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; PRIMARY INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEROCONVERSION; UNINDEXED SEQUENCE; UPREGULATION; VIRUS LOAD;

ADULT; AMINO ACID SUBSTITUTION; CD4 LYMPHOCYTE COUNT; EVOLUTION, MOLECULAR; FEMALE; GENETIC VARIATION; HIV INFECTIONS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; MALE; MUTATION, MISSENSE; PLASMA; SELECTION, GENETIC; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTION, GENETIC; VIRAL LOAD; VIRUS REPLICATION;

EID: 84877353853     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03297-12     Document Type: Article

References (98)

1. United Nations Programme on HIV/AIDS (UNAIDS). 2011. Report on the global AIDS epidemic. Joint United Nations Programme on HIV/ AIDS (UNAIDS), Geneva, Switzerland.
2. Lingappa JR, Hughes JP, Wang RS, Baeten JM, Celum C, Gray GE, Stevens WS, Donnell D, Campbell MS, Farquhar C, Essex M, Mullins JI, Coombs RW, Rees H, Corey L, Wald A. 2010. Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One 5:e12598. doi:10.1371/journal.pone.0012598.
3. Modjarrad K, Chamot E, Vermund SH. 2008. Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. AIDS 22:2179-2185.
4. Romani B, Engelbrecht S, Glashoff RH. 2010. Functions of Tat: the versatile protein of human immunodeficiency virus type 1. J. Gen. Virol. 91:1-12.
5. Li JC, Lee DC, Cheung BK, Lau AS. 2005. Mechanisms for HIV Tat upregulation of IL-10 and other cytokine expression: kinase signaling and PKR-mediated immune response. FEBS Lett. 579:3055-3062.
6. Matsui M, Warburton RJ, Cogswell PC, Baldwin AS, Jr, Frelinger JA. 1996. Effects of HIV-1 Tat on expression of HLA class I molecules. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 11:233-240.
7. Zheng L, Yang YD, Lu GC, Salvato MS. 2005. Extracellular HIV Tat and Tat cysteine rich peptide increase CCR5 expression in monocytes. J. Zhejiang Univ. Sci. B 6:668-672.
8. Della Chiara G, Crotti A, Liboi E, Giacca M, Poli G, Lusic M. 2011. Negative regulation of HIV-1 transcription by a heterodimeric NFkappaB1/ p50 and C-terminally truncated STAT5 complex. J. Mol. Biol. 410:933-943.
9. Duverger A, Jones J, May J, Bibollet-Ruche F, Wagner FA, Cron RQ, Kutsch O. 2009. Determinants of the establishment of human immunodeficiency virus type 1 latency. J. Virol. 83:3078-3093.
10. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. 2006. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J. 25:139-149.
11. Feng S, Holland EC. 1988. HIV-1 tat trans-activation requires the loop sequence within tar. Nature 334:165-167.
12. Wei P, Garber ME, Fang SM, Fischer WH, Jones KA. 1998. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92:451-462.
13. Deng L, de la Fuente C, Fu P, Wang L, Donnelly R, Wade JD, Lambert P, Li H, Lee CG, Kashanchi F. 2000. Acetylation of HIV-1 Tat by CBP/ P300 increases transcription of integrated HIV-1 genome and enhances binding to core histones. Virology 277:278-295.
14. Benkirane M, Chun RF, Xiao H, Ogryzko VV, Howard BH, Nakatani Y, Jeang KT. 1998. Activation of integrated provirus requires histone acetyltransferase. p300 and P/CAF are coactivators for HIV-1 Tat. J. Biol. Chem. 273:24898-24905.
15. Hottiger MO, Nabel GJ. 1998. Interaction of human immunodeficiency virus type 1 Tat with the transcriptional coactivators p300 and CREB binding protein. J. Virol. 72:8252-8256.
16. Marzio G, Tyagi M, Gutierrez MI, Giacca M. 1998. HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter. Proc. Natl. Acad. Sci. U. S. A. 95:13519-13524.
17. Furia B, Deng L, Wu K, Baylor S, Kehn K, Li H, Donnelly R, Coleman T, Kashanchi F. 2002. Enhancement of nuclear factor-kappa B acetylation by coactivator p300 and HIV-1 Tat proteins. J. Biol. Chem. 277:4973-4980.
18. Ott M, Schnolzer M, Garnica J, Fischle W, Emiliani S, Rackwitz HR, Verdin E. 1999. Acetylation of the HIV-1 Tat protein by p300 is important for its transcriptional activity. Curr. Biol. 9:1489-1492.
19. Zhu Y, Pe'ery T, Peng J, Ramanathan Y, Marshall N, Marshall T, Amendt B, Mathews MB, Price DH. 1997. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev. 11:2622-2632.
20. Zhou Q, Yik JH. 2006. The yin and yang of P-TEFb regulation: implications for human immunodeficiency virus gene expression and global control of cell growth and differentiation. Microbiol. Mol. Biol. Rev. 70:646-659.
21. Demarchi F, Gutierrez MI, Giacca M. 1999. Human immunodeficiency virus type 1 tat protein activates transcription factor NF-kappaB through the cellular interferon-inducible, double-stranded RNA-dependent protein kinase, PKR. J. Virol. 73:7080-7086.
22. Rossi A, Mukerjee R, Ferrante P, Khalili K, Amini S, Sawaya BE. 2006. Human immunodeficiency virus type 1 Tat prevents dephosphorylation of Sp1 by TCF-4 in astrocytes. J. Gen. Virol. 87:1613-1623.
23. Roof P, Ricci M, Genin P, Montano MA, Essex M, Wainberg MA, Gatignol A, Hiscott J. 2002. Differential regulation of HIV-1 cladespecific B, C, and E long terminal repeats by NF-kappaB and the Tat transactivator. Virology 296:77-83.
24. Bachu M, Yalla S, Asokan M, Verma A, Neogi U, Sharma S, Murali RV, Mukthey AB, Bhatt R, Chatterjee S, Rajan RE, Cheedarla N, Yadavalli VS, Mahadevan A, Shankar SK, Rajagopalan N, Shet A, Saravanan S, Balakrishnan P, Solomon S, Vajpayee M, Satish KS, Kundu TK, Jeang KT, Ranga U. 2012. Multiple NF-kappaB sites in HIV-1 subtype C long terminal repeat confer superior magnitude of transcription and thereby the enhanced viral predominance. J. Biol. Chem. 287:44714-44735.
25. Montano MA, Nixon CP, Ndung'u T, Bussmann H, Novitsky VA, Dickman D, Essex M. 2000. Elevated tumor necrosis factor-alpha activation of human immunodeficiency virus type 1 subtype C in Southern Africa is associated with an NF-kappaB enhancer gain-of-function. J. Infect. Dis. 181:76-81.
26. Montano MA, Novitsky VA, Blackard JT, Cho NL, Katzenstein DA, Essex M. 1997. Divergent transcriptional regulation among expanding human immunodeficiency virus type 1 subtypes. J. Virol. 71:8657-8665.
27. van Opijnen T, Jeeninga RE, Boerlijst MC, Pollakis GP, Zetterberg V, Salminen M, Berkhout B. 2004. Human immunodeficiency virus type 1 subtypes have a distinct long terminal repeat that determines the replication rate in a host-cell-specific manner. J. Virol. 78:3675-3683.
28. Desfosses Y, Solis M, Sun Q, Grandvaux N, Van Lint C, Burny A, Gatignol A, Wainberg MA, Lin R, Hiscott J. 2005. Regulation of human immunodeficiency virus type 1 gene expression by clade-specific Tat proteins. J. Virol. 79:9180-9191.
29. Kandathil AJ, Kannangai R, Abraham OC, Pulimood SA, Sridharan G. 2009. Amino acid sequence divergence of Tat protein (exon1) of subtype B and C HIV-1 strains: does it have implications for vaccine development? Bioinformation 4:237-241.
30. Neogi U, Gupta S, Sahoo PN, Shet A, Rao SD, Ranga U, Prasad VR. 2012. Genetic characterization of HIV type 1 Tat exon 1 from a Southern Indian clinical cohort: identification of unique epidemiological signature residues. AIDS Res. Hum. Retroviruses 28:1152-1156.
31. Clark SJ, Saag MS, Decker WD, Campbell-Hill S, Roberson JL, Veldkamp PJ, Kappes JC, Hahn BH, Shaw GM. 1991. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N. Engl. J. Med. 324:954-960.
32. Daar ES, Moudgil T, Meyer RD, Ho DD. 1991. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N. Engl. J. Med. 324:961-964.
33. Kaufmann GR, Cunningham P, Kelleher AD, Zaunders J, Carr A, Vizzard J, Law M, Cooper DA. 1998. Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. The Sydney Primary HIV Infection Study Group. J. Infect. Dis. 178:1812-1815.
34. Mellors JW, Kingsley LA, Rinaldo CR, Jr, Todd JA, Hoo BS, Kokka RP, Gupta P. 1995. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann. Intern. Med. 122:573-579.
35. Novitsky V, Ndung'u T, Wang R, Bussmann H, Chonco F, Makhema J, De Gruttola V, Walker BD, Essex M. 2011. Extended high viremics: a substantial fraction of individuals maintain high plasma viral RNA levels after acute HIV-1 subtype C infection. AIDS 25:1515-1522.
36. Novitsky V, Wang R, Bussmann H, Lockman S, Baum M, Shapiro R, Thior I, Wester C, Wester CW, Ogwu A, Asmelash A, Musonda R, Campa A, Moyo S, van Widenfelt E, Mine M, Moffat C, Mmalane M, Makhema J, Marlink R, Gilbert P, Seage GR, III, DeGruttola V, Essex M. 2010. HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the "test-and-treat" approach to reduce HIV transmission. PLoS One 5:e10148. doi:10.1371/journal.pone.0010148.
37. Yukl S, Pillai S, Li P, Chang K, Pasutti W, Ahlgren C, Havlir D, Strain M, Gunthard H, Richman D, Rice AP, Daar E, Little S, Wong JK. 2009. Latently-infected CD4 T cells are enriched for HIV-1 Tat variants with impaired transactivation activity. Virology 387:98-108.
38. Addo MM, Altfeld M, Rosenberg ES, Eldridge RL, Philips MN, Habeeb K, Khatri A, Brander C, Robbins GK, Mazzara GP, Goulder PJ, Walker BD. 2001. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc. Natl. Acad. Sci. U. S. A. 98:1781-1786.
39. Allen TM, O'Connor DH, Jing P, Dzuris JL, Mothe BR, Vogel TU, Dunphy E, Liebl ME, Emerson C, Wilson N, Kunstman KJ, Wang X, Allison DB, Hughes AL, Desrosiers RC, Altman JD, Wolinsky SM, Sette A, Watkins DI. 2000. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407:386-390.
40. Campbell GR, Loret EP. 2009. What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine? Retrovirology 6:50. doi:10.1186/1742-4690-6-50.
41. Vider-Shalit T, Almani M, Sarid R, Louzoun Y. 2009. The HIV hide and seek game: an immunogenomic analysis of the HIV epitope repertoire. AIDS 23:1311-1318.
42. Rezza G, Fiorelli V, Dorrucci M, Ciccozzi M, Tripiciano A, Scoglio A, Collacchi B, Ruiz-Alvarez M, Giannetto C, Caputo A, Tomasoni L, Castelli F, Sciandra M, Sinicco A, Ensoli F, Butto S, Ensoli B. 2005. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. J. Infect. Dis. 191:1321-1324.
43. Rodriguez SK, Sarr AD, Olorunnipa O, Popper SJ, Gueye-Ndiaye A, Traore I, Dia MC, Mboup S, Kanki PJ. 2006. The absence of anti-Tat antibodies is associated with risk of disease progression in HIV-2 infection. J. Infect. Dis. 194:760-763.
44. Allard SD, De Keersmaecker B, de Goede AL, Verschuren EJ, Koetsveld J, Reedijk ML, Wylock C, De Bel AV, Vandeloo J, Pistoor F, Heirman C, Beyer WE, Eilers PH, Corthals J, Padmos I, Thielemans K, Osterhaus AD, Lacor P, van der Ende ME, Aerts JL, van Baalen CA, Gruters RA. 2012. A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption. Clin. Immunol. 142:252-268.
45. Ensoli B, Bellino S, Tripiciano A, Longo O, Francavilla V, Marcotullio S, Cafaro A, Picconi O, Paniccia G, Scoglio A, Arancio A, Ariola C, Ruiz Alvarez MJ, Campagna M, Scaramuzzi D, Iori C, Esposito R, Mussini C, Ghinelli F, Sighinolfi L, Palamara G, Latini A, Angarano G, Ladisa N, Soscia F, Mercurio VS, Lazzarin A, Tambussi G, Visintini R, Mazzotta F, Di Pietro M, Galli M, Rusconi S, Carosi G, Torti C, Di Perri G, Bonora S, Ensoli F, Garaci E. 2010. Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One 5:e13540. doi:10.1371/journal.pone.0013540.
46. Ensoli B, Fiorelli V, Ensoli F, Lazzarin A, Visintini R, Narciso P, Di Carlo A, Tripiciano A, Longo O, Bellino S, Francavilla V, Paniccia G, Arancio A, Scoglio A, Collacchi B, Ruiz Alvarez MJ, Tambussi G, Tassan Din C, Palamara G, Latini A, Antinori A, D'Offizi G, Giuliani M, Giulianelli M, Carta M, Monini P, Magnani M, Garaci E. 2009. The preventive phase I trial with the HIV-1 Tat-based vaccine. Vaccine 28: 371-378.
47. Novitsky V, Lagakos S, Herzig M, Bonney C, Kebaabetswe L, Rossenkhan R, Nkwe D, Margolin L, Musonda R, Moyo S, Woldegabriel E, van Widenfelt E, Makhema J, Essex M. 2009. Evolution of proviral gp120 over the first year of HIV-1 subtype C infection. Virology 383:47-59.
48. Novitsky V, Woldegabriel E, Wester C, McDonald E, Rossenkhan R, Ketunuti M, Makhema J, Seage GR, III, Essex M. 2008. Identification of primary HIV-1C infection in Botswana. AIDS Care 20:806-811.
49. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, Heldebrant C, Smith R, Conrad A, Kleinman SH, Busch MP. 2003. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17:1871-1879.
50. Rossenkhan R, Novitsky V, Sebunya TK, Musonda R, Gashe BA, Essex M. 2011. Viral diversity and diversification of major non-structural genes vif, vpr, vpu, tat exon 1 and rev exon 1 during primary HIV-1 subtype C infection. PLoS One 7:e35491. doi:10.1371/journal.pone.0035491.
51. Liu SL, Rodrigo AG, Shankarappa R, Learn GH, Hsu L, Davidov O, Zhao LP, Mullins JI. 1996. HIV quasispecies and resampling. Science 273:415-416.
52. Posada D. 2008. jModelTest: phylogenetic model averaging. Mol. Biol. Evol. 25:1253-1256.
53. Guindon S, Gascuel O. 2003. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst. Biol. 52:696-704.
54. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 28:2731-2739.
55. Murrell B, Wertheim JO, Moola S, Weighill T, Scheffler K, Kosakovsky Pond SL. 2012. Detecting individual sites subject to episodic diversifying selection. PLoS Genet. 8:e1002764. doi:10.1371/journal.pgen.1002764.
56. Pond SLK, Frost SDW, Muse SV. 2005. HyPhy: hypothesis testing using phylogenies. Bioinformatics 21:676-679.
57. Kosakovsky Pond SL, Murrell B, Fourment M, Frost SDW, Delport W, Scheffler K. 2011. A random effects branch-site model for detecting episodic diversifying selection. Mol. Biol. Evol. 28:3033-3043.
58. Hasegawa M, Kishino H, Yano T. 1985. Dating of the human-ape splitting by a molecular clock of mitochondrial DNA. J. Mol. Evol. 22:160-174.
59. Muse SV, Gaut BS. 1994. A likelihood approach for comparing synonymous and nonsynonymous nucleotide substitution rates, with application to the chloroplast genome. Mol. Biol. Evol. 11:715-724.
60. Humphrey W, Dalke A, Schulten K. 1996. VMD: visual molecular dynamics. J. Mol. Graph. 14:33-38, 27-28.
61. Novitsky V, Wang R, Margolin L, Baca J, Kebaabetswe L, Rossenkhan R, Bonney C, Herzig M, Nkwe D, Moyo S, Musonda R, Woldegabriel E, van Widenfelt E, Makhema J, Lagakos S, Essex M. 2009. Timing constraints of in vivo gag mutations during primary HIV-1 subtype C infection. PLoS One 4:e7727. doi:10.1371/journal.pone.0007727.
62. Listgarten J, Brumme Z, Kadie C, Xiaojiang G, Walker B, Carrington M, Goulder P, Heckerman D. 2008. Statistical resolution of ambiguous HLA typing data. PLoS Comput. Biol. 4:e1000016. doi:10.1371/journal .pcbi.1000016.
63. Heckerman D, Kadie C, Listgarten J. 2007. Leveraging information across HLA alleles/supertypes improves epitope prediction. J. Comput. Biol. 14:736-746.
64. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, Ratner L, Kappes JC, Shaw GM, Hunter E. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74:8358-8367.
65. Platt EJ, Bilska M, Kozak SL, Kabat D, Montefiori DC. 2009. Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. J. Virol. 83:8289-8292.
66. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. 1998. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72: 2855-2864.
67. Takeuchi Y, McClure MO, Pizzato M. 2008. Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J. Virol. 82:12585-12588.
68. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
69. 1. Biometrika 60:613-622.
70. Benjamini Y, Hochberg Y. 1995. Controlling false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. 57:289-300.
71. Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, Keele BF, Derdeyn CA, Farmer P, Hunter E, Allen S, Manigart O, Mulenga J, Anderson JA, Swanstrom R, Haynes BF, Athreya GS, Korber BT, Sharp PM, Shaw GM, Hahn BH. 2008. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by singlegenome amplification and sequencing. J. Virol. 82:3952-3970.
72. Dey SS, Xue Y, Joachimiak MP, Friedland GD, Burnett JC, Zhou Q, Arkin AP, Schaffer DV. 2012. Mutual information analysis reveals coevolving residues in Tat that compensate for two distinct functions in HIV-1 gene expression. J. Biol. Chem. 287:7945-7955.
73. Tahirov TH, Babayeva ND, Varzavand K, Cooper JJ, Sedore SC, Price DH. 2010. Crystal structure of HIV-1 Tat complexed with human PTEFb. Nature 465:747-751.
74. Novitsky V, Cao H, Rybak N, Gilbert P, McLane MF, Gaolekwe S, Peter T, Thior I, Ndung'u T, Marlink R, Lee TH, Essex M. 2002. Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C. J. Virol. 76:10155-10168.
75. Dormeyer W, Dorr A, Ott M, Schnolzer M. 2003. Acetylation of the HIV-1 Tat protein: an in vitro study. Anal. Bioanal. Chem. 376:994-1005.
76. Pagans S, Kauder SE, Kaehlcke K, Sakane N, Schroeder S, Dormeyer W, Trievel RC, Verdin E, Schnolzer M, Ott M. 2010. The cellular lysine methyltransferase Set7/9-KMT7 binds HIV-1 TAR RNA, monomethylates the viral transactivator Tat, and enhances HIV transcription. Cell Host Microbe 7:234-244.
77. Van Duyne R, Easley R, Wu W, Berro R, Pedati C, Klase Z, Kehn-Hall K, Flynn EK, Symer DE, Kashanchi F. 2008. Lysine methylation of HIV-1 Tat regulates transcriptional activity of the viral LTR. Retrovirology 5:40. doi:10.1186/1742-4690-5-40.
78. Xie B, Invernizzi CF, Richard S, Wainberg MA. 2007. Arginine methylation of the human immunodeficiency virus type 1 Tat protein by PRMT6 negatively affects Tat interactions with both cyclin T1 and the Tat transactivation region. J. Virol. 81:4226-4234.
79. Deng L, Wang D, de la Fuente C, Wang L, Li H, Lee CG, Donnelly R, Wade JD, Lambert P, Kashanchi F. 2001. Enhancement of the p300 HAT activity by HIV-1 Tat on chromatin DNA. Virology 289:312-326.
80. Ammosova T, Berro R, Jerebtsova M, Jackson A, Charles S, Klase Z, Southerland W, Gordeuk VR, Kashanchi F, Nekhai S. 2006. Phosphorylation of HIV-1 Tat by CDK2 in HIV-1 transcription. Retrovirology 3:78. doi:10.1186/1742-4690-3-78.
81. Endo-Munoz L, Warby T, Harrich D, McMillan NA. 2005. Phosphorylation of HIV Tat by PKR increases interaction with TAR RNA and enhances transcription. Virol. J. 2:17. doi:10.1186/1743-422X-2-17.
82. Rice AP, Carlotti F. 1990. Mutational analysis of the conserved cysteinerich region of the human immunodeficiency virus type 1 Tat protein. J. Virol. 64:1864-1868.
83. Ranga U, Shankarappa R, Siddappa NB, Ramakrishna L, Nagendran R, Mahalingam M, Mahadevan A, Jayasuryan N, Satishchandra P, Shankar SK, Prasad VR. 2004. Tat protein of human immunodeficiency virus type 1 subtype C strains is a defective chemokine. J. Virol. 78:2586-2590.
84. Wong JK, Campbell GR, Spector SA. 2010. Differential induction of interleukin-10 in monocytes by HIV-1 clade B and clade C Tat proteins. J. Biol. Chem. 285:18319-18325.
85. Amendt BA, Hesslein D, Chang LJ, Stoltzfus CM. 1994. Presence of negative and positive cis-acting RNA splicing elements within and flanking the first tat coding exon of human immunodeficiency virus type 1. Mol. Cell. Biol. 14:3960-3970.
86. Amendt BA, Si ZH, Stoltzfus CM. 1995. Presence of exon splicing silencers within human immunodeficiency virus type 1 tat exon 2 and tat-rev exon 3: evidence for inhibition mediated by cellular factors. Mol. Cell. Biol. 15:4606-4615.
87. Jacquenet S, Mereau A, Bilodeau PS, Damier L, Stoltzfus CM, Branlant C. 2001. A second exon splicing silencer within human immunodeficiency virus type 1 tat exon 2 represses splicing of Tat mRNA and binds protein hnRNP H. J. Biol. Chem. 276:40464-40475.
88. Ma M, Nath A. 1997. Molecular determinants for cellular uptake of Tat protein of human immunodeficiency virus type 1 in brain cells. J. Virol. 71:2495-2499.
89. Barillari G, Sgadari C, Fiorelli V, Samaniego F, Colombini S, Manzari V, Modesti A, Nair BC, Cafaro A, Sturzl M, Ensoli B. 1999. The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor. Blood 94:663-672.
90. Fiorelli V, Barillari G, Toschi E, Sgadari C, Monini P, Sturzl M, Ensoli B. 1999. IFN-gamma induces endothelial cells to proliferate and to invade the extracellular matrix in response to the HIV-1 Tat protein: implications for AIDS-Kaposi's sarcoma pathogenesis. J. Immunol. 162:1165-1170.
91. Mahlknecht U, Dichamp I, Varin A, Van Lint C, Herbein G. 2008. NF-kappaB-dependent control of HIV-1 transcription by the second coding exon of Tat in T cells. J. Leukoc. Biol. 83:718-727.
92. Smith SM, Pentlicky S, Klase Z, Singh M, Neuveut C, Lu CY, Reitz MS, Jr, Yarchoan R, Marx PA, Jeang KT. 2003. An in vivo replicationimportant function in the second coding exon of Tat is constrained against mutation despite cytotoxic T lymphocyte selection. J. Biol. Chem. 278: 44816-44825.
93. Chopera DR, Mlotshwa M, Woodman Z, Mlisana K, de Assis Rosa D, Martin DP, Abdool Karim S, Gray CM, Williamson C. 2011. Virological and immunological factors associated with HIV-1 differential disease progression in HLA-B 58:01-positive individuals. J. Virol. 85:7070-7080.
94. De Groot AS, Rivera DS, McMurry JA, Buus S, Martin W. 2008. Identification of immunogenic HLA-B7 "Achilles' heel" epitopes within highly conserved regions of HIV. Vaccine 26:3059-3071.
95. Frahm N, Kiepiela P, Adams S, Linde CH, Hewitt HS, Sango K, Feeney ME, Addo MM, Lichterfeld M, Lahaie MP, Pae E, Wurcel AG, Roach T, St John MA, Altfeld M, Marincola FM, Moore C, Mallal S, Carrington M, Heckerman D, Allen TM, Mullins JI, Korber BT, Goulder PJ, Walker BD, Brander C. 2006. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat. Immunol. 7:173-178.
96. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, Chetty S, Rathnavalu P, Moore C, Pfafferott KJ, Hilton L, Zimbwa P, Moore S, Allen T, Brander C, Addo MM, Altfeld M, James I, Mallal S, Bunce M, Barber LD, Szinger J, Day C, Klenerman P, Mullins J, Korber B, Coovadia HM, Walker BD, Goulder PJ. 2004. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432:769-775.
97. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, Reddy S, de Pierres C, Mncube Z, Mkhwanazi N, Bishop K, van der Stok M, Nair K, Khan N, Crawford H, Payne R, Leslie A, Prado J, Prendergast A, Frater J, McCarthy N, Brander C, Learn GH, Nickle D, Rousseau C, Coovadia H, Mullins JI, Heckerman D, Walker BD, Goulder P. 2007. CD8 T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13:46-53.
98. Rousseau CM, Daniels MG, Carlson JM, Kadie C, Crawford H, Prendergast A, Matthews P, Payne R, Rolland M, Raugi DN, Maust BS, Learn GH, Nickle DC, Coovadia H, Ndung'u T, Frahm N, Brander C, Walker BD, Goulder PJ, Bhattacharya T, Heckerman DE, Korber BT, Mullins JI. 2008. HLA class I-driven evolution of human immunodeficiency virus type 1 subtype c proteome: immune escape and viral load. J. Virol. 82:6434-6446.